News for Zelira Therapeutics Limited (ZLD.AX)

A solid rise in the share prices of the big miners helped the Australian share market to lift on the last day of trade for the week.

The ASX 200 finished the day higher, up 0.2 per cent, after the US house of representatives passed a bill to suspend the debt ceiling.

The market closed lower today, with the ASX200 down 1.6 per cent to 7,091.3 points.

Perth-based Zelira Therapeutics (ASX: ZLD) has confirmed its cannabinoid-based diabetic nerve pain drug ZLT-L-007 has outperformed Pfizer’s commercially-available medication Lyrica (Pregabalin) in a multi-arm, head-to-head, US-based clinical trial.

The ASX is expected to drop on a fresh week as further concerns arise over the US debt ceiling and its potential repercussions on Wall Street.

New studies have confirmed that medical cannabis helps relieve cancer pain, or side effects from cancer treatment.

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

The date April 20th has become an unofficial holiday among cannabis enthusiasts who now call it the World Marijuana Day.

Research finds finds most Australians are still medicating with illicit cannabis, although numbers accessing legal prescription have risen.

The first of new products is set to be delivered by the end of FY23.

On Stockhead today, We're kicking some cancer ass, as our American friends would say. When not facing another banking crisis. And lithium!

Goldies were the winners today, as the ASX shuddered to a 0.6% slide in the wake of America's Silicon Valley Bank falling in a heap last week.

“In terms of stability, not all products containing CBD are created equal, and quality control can be a problem,” BOD MD Jo Patterson said.

Twitter has become the first social media platform to give cannabis advertising the all-clear - in US states where weed is legal.

On Stockhead today, Sprott says welcome everyone, to the battery metals Super Cycle. It's going to be a wild ride.

How AIC Mines plans to grow to a mid-tier - fast, an actual expert's view on when crypto will surge again, and is The Star a Buy or Broken Forever?

The ASX has weasled its way to +0.08%, BluGlass has soared after making a sale and Meta wants you to pay to be sold to its advertisers.

The ASX rare earths plays getting their Big Boy Pants in 2023, tips with MOATs in them, and our pet day trader gets bankered.

The ASX has waddled to a -0.85% result on a day that saw Megado rewarded for buying a bit of Quebec, and two titans of industry going to war in WA.